142 related articles for article (PubMed ID: 30519542)
21. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
23. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials.
Liu Y; Ye G; Yan D; Zhang L; Fan F; Feng J
Oncotarget; 2017 Sep; 8(42):72950-72958. PubMed ID: 29069839
[TBL] [Abstract][Full Text] [Related]
24. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.
Beusterien K; Grinspan J; Kuchuk I; Mazzarello S; Dent S; Gertler S; Bouganim N; Vandermeer L; Clemons M
Oncologist; 2014 Feb; 19(2):127-34. PubMed ID: 24473225
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
[TBL] [Abstract][Full Text] [Related]
26. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
[TBL] [Abstract][Full Text] [Related]
27. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis.
Lalla D; Carlton R; Santos E; Bramley T; D'Souza A
Springerplus; 2014; 3():350. PubMed ID: 26034663
[TBL] [Abstract][Full Text] [Related]
28. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Alexopoulos A; Kouroussis C; Malamos N; Kakolyris S; Kalbakis K; Kosmas C; Mavroudis D; Agelaki S; Vlachonicolis J; Sarra E; Rigatos G; Georgoulias V
Ann Oncol; 2001 Jun; 12(6):793-8. PubMed ID: 11484954
[TBL] [Abstract][Full Text] [Related]
30. How to maximize the efficacy of taxanes in breast cancer.
Tubiana-Hulin M
Cancer Treat Rev; 2005; 31 Suppl 4():S3-9. PubMed ID: 16360546
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
[TBL] [Abstract][Full Text] [Related]
33. Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer.
Reinisch M; Marschner N; Otto T; Korfel A; Stoffregen C; Wöckel A
Breast Care (Basel); 2021 Oct; 16(5):491-499. PubMed ID: 34720809
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
35. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
36. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
37. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
Palumbo R; Sottotetti F; Bernardo A
Ther Adv Med Oncol; 2016 May; 8(3):209-29. PubMed ID: 27239239
[TBL] [Abstract][Full Text] [Related]
38. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial.
Kellett N; West F; Finlay AY
Br J Dermatol; 2006 Mar; 154(3):524-32. PubMed ID: 16445786
[TBL] [Abstract][Full Text] [Related]
39. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
40. The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.
MacEwan JP; Doctor J; Mulligan K; May SG; Batt K; Zacker C; Lakdawalla D; Goldman D
MDM Policy Pract; 2019; 4(1):2381468319855386. PubMed ID: 31259249
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]